ClinVar Miner

Submissions for variant NM_031885.5(BBS2):c.1909_1910del (p.Met637fs)

dbSNP: rs1555521379
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000668190 SCV000792752 likely pathogenic Bardet-Biedl syndrome 2 2017-07-12 criteria provided, single submitter clinical testing
Invitae RCV001069811 SCV001235008 pathogenic Bardet-Biedl syndrome 2023-11-21 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Met637Glufs*12) in the BBS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS2 are known to be pathogenic (PMID: 11285252, 20177705, 24608809, 26518167). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with clinical features of Bardet-Biedl syndrome (PMID: 15666242). ClinVar contains an entry for this variant (Variation ID: 552850). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Blueprint Genetics RCV001074318 SCV001239891 likely pathogenic Retinal dystrophy 2019-06-29 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001069811 SCV001478761 likely pathogenic Bardet-Biedl syndrome 2021-01-29 criteria provided, single submitter clinical testing Variant summary: BBS2 c.1909_1910delAT (p.Met637GlufsX12) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251460 control chromosomes. c.1909_1910delAT has been reported in the literature as compound heterozygous with another pathogenic variant in a fetus affected with Bardet-Biedl Syndrome (e.g. Karmous-Benailly_2005). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories cited the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.